Zillion announced today that it partnered with Dexcom (Nasdaq:DXCM) to integrate its CGM technology with Zillion’s digital health platform. Needham, Massachusetts-based Zillion will connect Dexcom’s continuous glucose monitoring (CGM) platform with its digital health offering for the RestoreHealth program, enhancing RestoreHealth for employer and health system patients. “Type 2 diabetes continues to be a growing […]
Technology
Teva appoints former Vertex exec as new head of R&D, CMO
Teva Pharmaceuticals (NYSE:TEVA) announced today that it appointed Dr. Eric A. Hughes as VP of global R&D and chief medical officer. Hughes’ employment becomes effective Aug. 1, 2022, and he will be based out of Tel Aviv, Israel-based Teva’s U.S. headquarters in Parsippany, New Jersey. The company develops generic and specialty medicines, including inhalation solutions. […]
CeQur is launching a discreet, convenient ‘wearable insulin pen’
CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable […]
Tandem Diabetes Care adds two new members to its board
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it appointed two new independent members to its board of directors. Myoung Cha and Joao Malagueira have been named to the San Diego-based automated insulin delivery technology developer’s board, effective yesterday. “We welcome Joao and Myoung to our board of directors at this exciting stage in Tandem’s evolution,” […]
Senseonics wins CE mark approval for 180-day Eversense E3 CGM
Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system. Germantown, Maryland-based Senseonics offered a previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days). Europe already had a 180-day Senseonics CGM system available (Eversense […]
Data supports Beta Bionics’ iLet bionic pancreas
Beta Bionics announced today that a trial of its iLet bionic pancreas met key endpoints, including reduced HbA1c. Dr. Roy W. Beck and clinical investigators presented the results of the multi-center, randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Read: The biggest stories […]
DarioHealth closes $50M loan facility with OrbiMed
DarioHealth (Nasdaq:DRIO) announced today that it closed a senior secured term loan facility worth up to $50 million. OrbiMed, a leading healthcare investor, will provide non-dilutive capital to fund the continued development of New York-based DarioHealth’s digital health platform for managing chronic diseases, including diabetes. According to a news release, the five-year, $50 million facility includes […]
Pear Therapeutics reports positive real-world data for chronic insomnia treatment
Pear Therapeutics (Nasdaq:PEAR) today announced real-world data from a trial of its Somryst prescription digital therapeutic (PDT). Data showed that Somryst, the only FDA-authorized PDT for treating chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity both immediately following treatment and at six-months follow-up. Boston-based Pear Therapeutics presented results at the […]
The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions
For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space. Major players like Dexcom, Medtronic, Abbott, Insulet and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table. […]
Digital therapeutics developer Better Therapeutics names new CEO
Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Frank Karbe as its new president and CEO. San Francisco-based Better Therapeutics develops prescription digital therapeutics (PDTs) based on nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases. Karbe will join the company as president and CEO and will serve as a member […]
